Investor Relations

IceCure is transforming healthcare by bringing the choice of advanced minimally invasive cryoablation treatment options for benign and malignant tumors to women's health and interventional oncology.

Latest News

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

View Press Release

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

View Press Release

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

View Press Release
Company Presentation

Latest Presentation

Company Presentation

View Presentation View All Presentations

Upcoming Event

Special General Meeting of Shareholders

View Event Add to Calendar View All Events

Company Overview

IceCure is transforming healthcare by bringing the choice of advanced minimally invasive cryoablation treatment options for benign and malignant tumors to women's health and interventional oncology. Its liquid-nitrogen based systems use ultra cold temperatures to destroy tumors by freezing them. Supported by clinical experience across multiple areas of cancer care, IceCure is opening the door for quick, convenient office-based and CT room procedures. Cryoablation - It's your choice.

View Executive Team View Board of Directors

Latest Financial Results

Q3 2025

Quarter Ended Sep 30, 2025

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Report Links

Stock Snapshot

IR Contacts

Headquarters

IceCure Medical Ltd.
7 Ha’Eshel Street
PO Box 3163
Caesarea 3079504
Israel
T: +972-4-623-0333
F: +972-4-623-0222
investors@icecure-medical.com

Investor Relations

EVC Group
Michael Polyviou
Todd Kehrli
T: +1-732-933-2755
investors@icecure-medical.com
https://www.evcgroup.com

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
F: 646-536-3179
info@vstocktransfer.com